Inhibition of annexin V binding to cardiolipin and thrombin generation in an unselected population with venous thrombosis

Journal of Rheumatology

Volumn 30, Issue 9, 2003, Pages 1990-1993

  Hanly, John G ^a   Smith, Stephanie A ^b   Anderson, David ^b  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^b NONE

Author keywords

Annexin V; Antiphospholipid antibodies; Thrombin

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN; LIPOCORTIN 5; PHOSPHOLIPID ANTIBODY; THROMBIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EMERGENCY WARD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG EMBOLISM; MALE; PRIORITY JOURNAL; PROTEIN BINDING; VEIN THROMBOSIS;

ANNEXIN A5; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIBODIES, MONOCLONAL; BINDING SITES; CARDIOLIPINS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LOGISTIC MODELS; MALE; PULMONARY EMBOLISM; REFERENCE VALUES; RISK ASSESSMENT; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; THROMBIN; VENOUS THROMBOSIS;

EID: 0042694704     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544-7.
2. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990;87:4120-4.
3. Oosting JD, Derksen RH, Bobbink IW, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood 1993;81:2618-25.
4. Permpikul P, Rao LV, Rapaport SI. Functional and binding studies of the roles of prothrombin and beta 2-glycoprotein I in the expression of lupus anticoagulant activity. Blood 1994;83:2878-92.
5. Del Papa N, Meroni PL, Tincani A, et al. Relationship between anti-phospholipid and anti-endothelial cell antibodies: further characterization of the reactivity on resting and cytokine-activated endothelial cells. Clin Exp Rheumatol 1992;10:37-42.
6. Del Papa N, Guidali L, Sala A, et al. Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum 1997;40:551-61.
7. Simantov R, La Sala JM, Lo SK, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995;96:2211-9.
8. Asano T, Furie BC, Furie B. Platelet binding properties of monoclonal lupus autoantibodies produced by human hybridomas. Blood 1985;66:1254-60.
9. Rauch J, Meng QH, Tannenbaum H. Lupus anticoagulant and antiplatelet properties of human hybridoma autoantibodies. J Immunol 1987;139:2598-604.
10. Khamashta MA, Harris EN, Gharavi AE, et al. Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis 1988;47:849-54.
11. Galli M, Ruggeri L, Barbui T. Differential effects of anti-beta2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. Blood 1998;91:1999-2004.
12. Rand JH, Wu XX, Andree HA, et al. Pregnancy loss in the antiphospholipid-antibody syndrome - a possible thrombogenic mechanism. N Engl J Med 1997;337:154-60.
13. Rand JH, Wu XX, Andree HA, et al. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a "lupus procoagulant" phenomenon. Blood 1998;92:1652-60.
14. Hanly JG, Smith SA. Anti-beta2-glycoprotein I (GPI) autoantibodies, annexin V binding and the anti-phospholipid syndrome. Clin Exp Immunol 2000;120:537-43.
15. Hanly JG, Smith SA. Anti-beta2-glycoprotein I autoantibodies, in vitro thrombin generation, and the antiphospholipid syndrome. J Rheumatol 2000;27:2152-9.
16. Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995;86:3685-91.
17. Simioni P, Prandoni P, Zanon E, et al. Deep venous thrombosis and lupus anticoagulant. A case-control study. Thromb Haemost 1996;76:187-9.
18. Anticardiolipin antibodies and the risk of recurrent thromboocclusive events and death. The Antiphospholipid Antibodies and Stroke Study Group (APASS). Neurology 1997;48:91-4.
19. Willems GM, Janssen MP, Comfurius P, Galli M, Zwaal RF, Bevers EM. Competition of annexin V and anticardiolipin antibodies for binding to phosphatidylserine containing membranes. Biochemistry 2000;39:1982-9.
20. Thiagarajan P, Benedict CR. Inhibition of arterial thrombosis by recombinant annexin V in a rabbit carotid artery injury model. Circulation 1997;96:2339-47.
21. van Heerde WL, Sakariassen KS, Hemker HC, Sixma JJ, Reutelingsperger CP, de Groot PG. Annexin V inhibits the procoagulant activity of matrices of TNF-stimulated endothelium under blood flow conditions. Arterioscler Thromb 1994;14;824-30.